Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tooth-Derived graft may boost jaw bone healing after cyst removal

NCT ID NCT07652216

Disease control Sponsor: Jagiellonian University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using a patient's own tooth-derived bone graft (ADDM) combined with a platelet-rich fibrin (A-PRF) can improve bone healing after removing a dentigerous cyst and an impacted wisdom tooth. Thirty-five adults with this condition will receive either standard care (blood clot), A-PRF alone, or A-PRF plus ADDM. The main goal is to measure bone defect reduction on CT scans at 6 and 12 months, with pain as a secondary outcome.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Autogenous Demineralized Dentin Matrix (ADDM) and Advanced Platelet-Rich Fibrin (A-PRF)
What this could lead to
If successful, this approach could speed up bone regeneration and reduce pain after jaw cyst surgery, offering a better recovery option.
What could go wrong
This is a small, early-stage study with only 35 participants, so results may not apply to everyone. The treatments are experimental and may not improve healing over natural blood clot formation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

35 people

The number who actually took part.

Started

Apr 2024

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients diagnosed with dentigerous cysts associated with impacted mandibular third molars * Indication for surgical enucleation and tooth extraction * Ability to provide informed consent * Availability for postoperative follow-up examinations and CBCT assessment Exclusion Criteria: * Acute local infection at the surgical site * Systemic diseases affecting bone healing or tissue regeneration * Immunosuppressive therapy * Pregnancy or breastfeeding * Hematological disorders affecting platelet function, coagulation, or fibrin formation (including thrombocytopenia, coagulopathies, or anticoagulant therapy). * History of radiotherapy in the head and neck region * Use of medications affecting bone metabolism * Heavy smoking * Inability to comply with follow-up visits or postoperative recommendations

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autogenous dentin graft are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dentigerous cyst

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autogenous dentin graft Bone regeneration Demineralized dentin matrix Dentigerous cyst Dentin matrix Impact molar Impacted lower third molar Impacted mandibular third molar Mandible cyst Platelet rich fibrin

Contacts and locations

Locations

  • Department of Oral Surgery, Institute of Dentistry, Jagiellonian University Medical College

    Krakow, Malopolska, 31-155, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.